Dr. Susan Coote:

I have a briefing note on that in front of me. We are delighted to see that Sativex has been recommended for reimbursement through a managed-access programme. It is a start, as the Deputy implied, and it could be rolled out further. The primary purpose of the drug is to treat moderate to severe spasticity, or stiffness in the limbs, caused by multiple sclerosis. We are delighted to see the drug included. It is the start of greater access to the drug. There is very good evidence that it is beneficial in treating the symptoms of a range of conditions.